Psoriasis of Scalp Clinical Trial
Official title:
Immune Spatial Features of Guselkumab Cutaneous Response
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
This is a one-arm, open-label study to examine the effect of Guselkumab . Guselkumab is a FDA-approved medication for the treatment of psoriasis. This study will examine how Guselkumab affects immune cells within scalp psoriasis lesions. Ten subjects with moderate to severe scalp psoriasis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with Guselkumab treatment response. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00243464 -
Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis
|
Phase 3 | |
| Recruiting |
NCT05144165 -
Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines
|
||
| Completed |
NCT05105139 -
Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
|
||
| Completed |
NCT00216827 -
Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis
|
Phase 3 | |
| Recruiting |
NCT04099979 -
A Pilot Study to Explore the Role of Gut Flora in Psoriasis
|
||
| Not yet recruiting |
NCT03553433 -
Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis
|
Phase 4 | |
| Recruiting |
NCT05938361 -
Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis
|
||
| Completed |
NCT00216879 -
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis
|
Phase 3 | |
| Completed |
NCT00216840 -
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis
|
Phase 3 |